Nectar Lifesciences Intrinsic Value
Nectar Lifesciences (NECLIFE) median intrinsic value is ₹35.90 from 3 valuation models (range ₹25–₹36), vs current price ₹14.36 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. Browse Nectar Lifesciences annual reports for revenue, profit, balance sheet and cash flow data.
NECLIFE Valuation Methods Summary — DCF, Graham Number & P/E
Nectar Lifesciences intrinsic value across 3 models vs current price ₹14.36 — upside/downside and value range per method. For current market price and key ratios, visit Nectar Lifesciences share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹35.90 | ₹32.31 - ₹39.49 | +150.0% | Book Value/Share: ₹306.32, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹25.26 | ₹22.73 - ₹27.79 | +75.9% | Revenue/Share: ₹12.63, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹35.90 | ₹28.72 - ₹43.08 | +150.0% | CF Growth: 15.0%, Discount: 15% |
NECLIFE Intrinsic Value vs Market Price — All Valuation Models
Nectar Lifesciences fair value range ₹25–₹36 vs current market price ₹14.36 across 3 valuation models. Also explore Nectar Lifesciences share price performance to track price trends across different timeframes.
NECLIFE Intrinsic Value Analysis — Undervalued or Overvalued?
Nectar Lifesciences median intrinsic value ₹35.90, current price ₹14.36 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of NECLIFE?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Nectar Lifesciences (NECLIFE) is ₹35.90 (median value). With the current market price of ₹14.36, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹25.26 to ₹35.90, indicating ₹25.26 - ₹35.90.
Is NECLIFE undervalued or overvalued?
Based on our multi-method analysis, Nectar Lifesciences (NECLIFE) appears to be trading below calculated value by approximately 150.0%.
NECLIFE Financial Health — Key Ratios vs Industry Benchmarks
Nectar Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 32.11 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -46.7% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Asset Turnover Ratio | 0.04x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
NECLIFE Cash Flow Quality — Operating & Free Cash Flow
Nectar Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹169 Cr | ₹148 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹225 Cr | ₹217 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹134 Cr | ₹134 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹95 Cr | ₹95 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹21 Cr | ₹7 Cr | Positive Free Cash Flow | 7/10 |